癌症免疫疗法药物研发外包市场 - 全球产业规模、份额、趋势、机会和预测，按药物类型、服务类型、癌症类型、地区和竞争细分，2020-2030 年

2024 年全球癌症免疫疗法药物研发外包市场价值为 12.9 亿美元，预计到 2030 年将达到 21.4 亿美元，预测期内复合年增长率为 8.80%。癌症免疫疗法药物研发外包是製药和生技产业内的专业服务模式。它涉及将癌症免疫疗法药物发现和开发过程的各个方面外包给外部服务提供者，通常称为合约研究组织（CRO）或合约开发和製造组织（CDMO）。这种外包模式旨在加速创新癌症免疫疗法的开发，同时允许製药公司利用外部的专业知识、基础设施和资源。癌症免疫疗法的药物发现过程通常涉及几个阶段，包括标靶识别、临床前研究、临床试验管理和监管部门批准。外包可以涵盖这些阶段的各个方面。与外包合作伙伴共担风险是製药业的常见策略。透过与外部专家合作，公司可以降低科学和财务风险。免疫检查点抑制剂、CAR-T细胞疗法和单株抗体等免疫治疗方法的快速发展和成功，引起了对该领域的极大兴趣和投资。个人化医疗的转变导致人们专注于为个别患者识别特定的生物标记和基因目标。这使得生物标誌物发现和药物开发的外包服务成为必要。患者越来越意识到免疫疗法是一种可行的癌症治疗选择，而且他们经常寻求这些疗法。患者需求的增加促使製药公司投资免疫疗法药物研发。随着研究对癌症的遗传和分子机制有了新的认识，人们对开发针对更广泛癌症类型（包括罕见癌症）的免疫疗法的关注度不断增加。将药物发现的某些方面（例如目标识别、临床前研究和临床试验管理）外包有助于製药公司降低研发成本并更有效地分配资源。

主要市场驱动因素

提高患者需求和意识

主要市场挑战

品质控制和标准化

主要市场趋势

增加对检查点抑制剂的研究

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第五章：全球癌症免疫治疗药物研发外包市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类型（单株抗体、免疫调节剂、癌症疫苗和溶瘤病毒疗法等）
  • 依服务类型（目标识别和验证、先导化合物筛选和表征、基于细胞的分析）
  • 依癌症类型（肺癌、乳癌、大肠癌、黑色素瘤、摄护腺癌、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：亚太地区癌症免疫治疗药物研发外包市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 7 章：欧洲癌症免疫疗法药物研发外包市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美癌症免疫疗法药物研发外包市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 9 章：南美洲癌症免疫疗法药物研发外包市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲癌症免疫疗法药物研发外包市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 13 章：全球癌症免疫疗法药物研发外包市场：SWOT 分析

第 14 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 15 章： 大环境分析

第 16 章：竞争格局

• Covance, Inc.
• Horizon Discovery Group PLC
• Crown Bioscience, Inc.
• Promega Corporation
• HD Biosciences Co., Ltd.
• BPS Bioscience, Inc.
• Genscript Biotech Corporation
• DiscoverX Corporation
• Celentyx Ltd.
• ImmunXperts SA

第 17 章：策略建议

第18章调查会社について・免责事项

Global Cancer Immunotherapy Drug Discovery Outsourcing Market was valued at USD 1.29 billion in 2024 and is expected to reach USD 2.14 billion by 2030 with a CAGR of 8.80% during the forecast period. Cancer Immunotherapy Drug Discovery Outsourcing is a specialized service model within the pharmaceutical and biotechnology industry. It involves the outsourcing of various aspects of the drug discovery and development process for cancer immunotherapies to external service providers, often known as Contract Research Organizations (CROs) or Contract Development and Manufacturing Organizations (CDMOs). This outsourcing model is designed to accelerate the development of innovative cancer immunotherapies while allowing pharmaceutical companies to leverage external expertise, infrastructure, and resources. The drug discovery process for cancer immunotherapies typically involves several stages, including target identification, preclinical research, clinical trial management, and regulatory approval. Outsourcing can cover various aspects of these stages. Sharing risks with outsourcing partners is a common strategy in the pharmaceutical industry. By partnering with external experts, companies can mitigate scientific and financial risks. The rapid development and success of immunotherapy approaches, such as immune checkpoint inhibitors, CAR-T cell therapies, and monoclonal antibodies, have driven significant interest and investment in the field. The shift toward personalized medicine has led to a focus on identifying specific biomarkers and genetic targets for individual patients. This necessitates outsourcing services for biomarker discovery and drug development. Patients are becoming more aware of immunotherapy as a viable cancer treatment option, and they often seek out these therapies. This increased patient demand drives pharmaceutical companies to invest in immunotherapy drug discovery. As research uncovers new insights into the genetic and molecular mechanisms of cancer, the focus on developing immunotherapies for a broader range of cancer types, including rare cancers, has increased. Outsourcing certain aspects of drug discovery, such as target identification, preclinical research, and clinical trial management, helps pharmaceutical companies reduce research and development costs and allocate resources more efficiently.

Key Market Drivers

Increasing Patient Demand and Awareness

Patients today have greater access to information about cancer treatment options, including immunotherapy, through the internet, social media, and patient advocacy groups. This increased awareness leads patients to seek out the latest and most promising therapies. Many patients with cancer are seeking innovative and more effective treatments, especially when traditional therapies have not yielded satisfactory results or are associated with significant side effects. Immunotherapies represent a promising and less toxic approach. Awareness about the concept of personalized medicine has grown. Patients are increasingly aware that cancer immunotherapies can be tailored to their specific genetic and molecular profiles, making them more effective and less likely to cause adverse effects. Patients are more willing to participate in clinical trials, as they recognize the potential benefits of receiving cutting-edge treatments. Clinical trials often rely on outsourcing services for various aspects, including patient recruitment and data management. Patient advocacy groups and organizations dedicated to specific types of cancer actively promote awareness about the latest treatments, including immunotherapies. They often collaborate with researchers and pharmaceutical companies, indirectly contributing to the growth of outsourcing services. As patients become more informed, they engage in discussions with their healthcare providers about treatment options, including immunotherapy. This dialogue drives interest in these therapies and encourages healthcare professionals to explore outsourcing for the latest treatments.

Key Market Challenges

Quality Control and Standardization

The drug discovery process for cancer immunotherapies is complex and continually evolving. Ensuring consistent quality and standards across different stages of this process, from target identification to clinical trials, is a significant challenge. Outsourcing projects often involve multiple sites, including research organizations, pharmaceutical companies, and contract research organizations (CROs). Coordinating and maintaining quality standards across these different entities can be challenging. Immunotherapy research and development employ a wide range of technologies and techniques, from genomics to cell-based assays. Standardizing procedures and ensuring quality across these diverse methods is essential. Quality control extends to data management and integration. Diverse data sources, such as genomics data, clinical trial data, and patient records, need to be standardized and integrated for comprehensive analysis.

Key Market Trends

Increasing Research in Checkpoint Inhibitors

Checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have demonstrated substantial clinical success in the treatment of various cancers, including melanoma, lung cancer, and more. This success has driven increased research and development in this area. Research is ongoing to explore the use of checkpoint inhibitors for a broader range of cancer types and stages. This expansion of indications requires extensive outsourcing services for clinical trial management and patient recruitment. Researchers are investigating combinations of checkpoint inhibitors with other immunotherapies, chemotherapy, targeted therapies, and radiation therapy. This approach requires extensive research and outsourcing support. Identifying predictive and prognostic biomarkers to guide the use of checkpoint inhibitors is a key focus of research. Outsourcing services play a critical role in biomarker discovery. The trend toward personalized medicine in cancer treatment emphasizes the need to identify which patients are most likely to benefit from checkpoint inhibitors. Outsourcing services contribute to this patient-centric approach.

Key Market Players

• Covance, Inc.
• Horizon Discovery Group PLC
• Crown Bioscience, Inc.
• Promega Corporation
• HD Biosciences Co., Ltd.
• BPS Bioscience, Inc.
• Genscript Biotech Corporation
• DiscoverX Corporation
• Celentyx Ltd.
• ImmunXperts SA

Report Scope:

In this report, the Global Cancer Immunotherapy Drug Discovery Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Immunotherapy Drug Discovery Outsourcing Market, By Service Type:

• Target Identification and Validation
• Lead Screening and Characterization
• Cell-based Assays

Cancer Immunotherapy Drug Discovery Outsourcing Market, By Drug Type:

• Monoclonal Antibodies
• Immunomodulators
• Cancer Vaccines and Oncolytic Viral Therapy
• others

Cancer Immunotherapy Drug Discovery Outsourcing Market, By Cancer Type:

• Lung
• Breast
• Colorectal
• Melanoma
• Prostate
• Others

Cancer Immunotherapy Drug Discovery Outsourcing Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Immunotherapy Drug Discovery Outsourcing Market.

Available Customizations:

Global Cancer Immunotherapy Drug Discovery Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy, others)
  • 5.2.2. By Service Type (Target Identification and Validation, Lead Screening and Characterization, Cell-based Assays)
  • 5.2.3. By Cancer Type (Lung, Breast, Colorectal, Melanoma, Prostate, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Service Type
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Service Type
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. India Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Service Type
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Australia Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Service Type
      • 6.3.3.2.3. By Cancer Type
  • 6.3.4. Japan Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Type
      • 6.3.4.2.2. By Service Type
      • 6.3.4.2.3. By Cancer Type
  • 6.3.5. South Korea Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Type
      • 6.3.5.2.2. By Service Type
      • 6.3.5.2.3. By Cancer Type

7. Europe Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Service Type
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Service Type
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. Germany Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Service Type
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. Spain Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Service Type
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Service Type
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. United Kingdom Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Service Type
      • 7.3.5.2.3. By Cancer Type

8. North America Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Service Type
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Service Type
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. Mexico Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Service Type
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Canada Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Service Type
      • 8.3.3.2.3. By Cancer Type

9. South America Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Service Type
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Service Type
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. Argentina Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Service Type
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. Colombia Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Service Type
      • 9.3.3.2.3. By Cancer Type

10. Middle East and Africa Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Service Type
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Service Type
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Saudi Arabia Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Service Type
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. UAE Cancer Immunotherapy Drug Discovery Outsourcing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Service Type
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Cancer Immunotherapy Drug Discovery Outsourcing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Covance, Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Horizon Discovery Group PLC
• 16.3. Crown Bioscience, Inc.
• 16.4. Promega Corporation
• 16.5. HD Biosciences Co., Ltd.
• 16.6. BPS Bioscience, Inc.
• 16.7. Genscript Biotech Corporation
• 16.8. DiscoverX Corporation
• 16.9. Celentyx Ltd.
• 16.10. ImmunXperts SA

17. Strategic Recommendations

18. About Us & Disclaimer